Autonomous Cortisol Secretion clinical trials at University of California Health

1 in progress, 0 open to eligible people

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
Sorry, not currently recruiting here
This will be a randomized, double-blind study to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor.
at UC Irvine UCLA

Our lead scientists for Autonomous Cortisol Secretion research studies include Qin Yang, MD Anthony Heaney, MD.

Last updated: January 26, 2023

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor